COMBINATION ANTI-CSF1R AND ANTI-PD-1 ANTIBODY COMBINATION THERAPY FOR PANCREATIC CANCER

• 收藏
• 分享

专利权人:

FIVE PRIME THERAPEUTICS, INC.;BRISTOL-MYERS SQUIBB COMPANY

发明人:

WONG, Brian,HAMBLETON, Julie,SIKORSKI, Robert,MASTELLER, Emma,HESTIR, Kevin,BELLOVIN, David,POWERS, Janine,LEE, Ernestine,LEWIS, Katherine E.,PERNA, Serena,CARLETON, Michael,XU, Ke,PHILLIPS, Penny,PAN

申请号：

SG11202001606X

公开号：

SG11202001606XA

申请日:

2018.09.12

申请国别(地区):

SG

年份:

2020

代理人:

摘要：

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/